Cargando…

Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein

A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Wenhui, Sun, Baoli, Mo, Jianyue, Zeng, Xiduo, Zhang, Guanqun, Wang, Lianxiang, Zhou, Qingfeng, Zhu, Ling, Li, Zhili, Xie, Qingmei, Bi, Yinzuo, Ma, Jingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070328/
https://www.ncbi.nlm.nih.gov/pubmed/25009824
http://dx.doi.org/10.1155/2014/810523
_version_ 1782322670779498496
author Lu, Wenhui
Sun, Baoli
Mo, Jianyue
Zeng, Xiduo
Zhang, Guanqun
Wang, Lianxiang
Zhou, Qingfeng
Zhu, Ling
Li, Zhili
Xie, Qingmei
Bi, Yinzuo
Ma, Jingyun
author_facet Lu, Wenhui
Sun, Baoli
Mo, Jianyue
Zeng, Xiduo
Zhang, Guanqun
Wang, Lianxiang
Zhou, Qingfeng
Zhu, Ling
Li, Zhili
Xie, Qingmei
Bi, Yinzuo
Ma, Jingyun
author_sort Lu, Wenhui
collection PubMed
description A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity study showed that pigs inoculated with QY1 P100 and P80 did not develop any significant PRRS clinic symptoms. However, mild-to-moderate clinical signs and acute HP-PRRSV symptoms of infection were observed in pigs inoculated with QY1 P60 and P5, respectively. Furthermore, we determined the whole genome sequences of these four intermediate viruses. The results showed that after 100 passages, compared to QY1 P5, a total of 32 amino acid mutations were found. Moreover, there were one nucleotide deletion and a unique 34-amino acid deletion found at 5′UTR and in nsp2 gene during the attenuation process, respectively. Such deletions were genetically stable in vivo. Following PRRSV experimental challenge, pigs inoculated with a single dose of QY1 P100 developed no significant clinic symptoms and well tolerated lethal challenge, while QY1 P80 group still developed mild fever in the clinic trial after challenge. Thus, we concluded that QY1 P100 was a promising and highly attenuated PRRSV vaccine candidate.
format Online
Article
Text
id pubmed-4070328
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40703282014-07-09 Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein Lu, Wenhui Sun, Baoli Mo, Jianyue Zeng, Xiduo Zhang, Guanqun Wang, Lianxiang Zhou, Qingfeng Zhu, Ling Li, Zhili Xie, Qingmei Bi, Yinzuo Ma, Jingyun J Immunol Res Research Article A porcine reproductive and respiratory syndrome virus (PRRSV) QY1 was serially passed on Marc-145 cells. Virulence of different intermediate derivatives of QY1 (P5, P60, P80, and P100) were determined. The study found that QY1 had been gradually attenuated during the in vitro process. Pathogenicity study showed that pigs inoculated with QY1 P100 and P80 did not develop any significant PRRS clinic symptoms. However, mild-to-moderate clinical signs and acute HP-PRRSV symptoms of infection were observed in pigs inoculated with QY1 P60 and P5, respectively. Furthermore, we determined the whole genome sequences of these four intermediate viruses. The results showed that after 100 passages, compared to QY1 P5, a total of 32 amino acid mutations were found. Moreover, there were one nucleotide deletion and a unique 34-amino acid deletion found at 5′UTR and in nsp2 gene during the attenuation process, respectively. Such deletions were genetically stable in vivo. Following PRRSV experimental challenge, pigs inoculated with a single dose of QY1 P100 developed no significant clinic symptoms and well tolerated lethal challenge, while QY1 P80 group still developed mild fever in the clinic trial after challenge. Thus, we concluded that QY1 P100 was a promising and highly attenuated PRRSV vaccine candidate. Hindawi Publishing Corporation 2014 2014-06-09 /pmc/articles/PMC4070328/ /pubmed/25009824 http://dx.doi.org/10.1155/2014/810523 Text en Copyright © 2014 Wenhui Lu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lu, Wenhui
Sun, Baoli
Mo, Jianyue
Zeng, Xiduo
Zhang, Guanqun
Wang, Lianxiang
Zhou, Qingfeng
Zhu, Ling
Li, Zhili
Xie, Qingmei
Bi, Yinzuo
Ma, Jingyun
Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
title Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
title_full Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
title_fullStr Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
title_full_unstemmed Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
title_short Attenuation and Immunogenicity of a Live High Pathogenic PRRSV Vaccine Candidate with a 32-Amino Acid Deletion in the nsp2 Protein
title_sort attenuation and immunogenicity of a live high pathogenic prrsv vaccine candidate with a 32-amino acid deletion in the nsp2 protein
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070328/
https://www.ncbi.nlm.nih.gov/pubmed/25009824
http://dx.doi.org/10.1155/2014/810523
work_keys_str_mv AT luwenhui attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT sunbaoli attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT mojianyue attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT zengxiduo attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT zhangguanqun attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT wanglianxiang attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT zhouqingfeng attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT zhuling attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT lizhili attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT xieqingmei attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT biyinzuo attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein
AT majingyun attenuationandimmunogenicityofalivehighpathogenicprrsvvaccinecandidatewitha32aminoaciddeletioninthensp2protein